<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37594896</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Tumor Marker Trajectories and Survival Analysis in Patients With Normal Carcinoembryonic Antigen Ranges After Colorectal Cancer Resection.</ArticleTitle><Pagination><StartPage>62</StartPage><EndPage>72</EndPage><MedlinePgn>62-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002894</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence regarding postoperative CEA for predicting long-term outcomes of colorectal cancer remains controversial, especially in patients with normal postoperative CEA.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the risk difference among different postoperative CEA trajectories in patients with normal postoperative CEA after curative colorectal cancer resection.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This cohort study was conducted at a comprehensive cancer center and included data retrieved from a prospectively collected database between January 2006 and December 2018.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with colorectal cancer who underwent surgery for primary stage I to III colorectal adenocarcinoma were included and those with postoperative CEA &gt;5&#x2009;ng/mL were excluded.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Standard curative radical resection was performed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Ten-year overall survival and disease-free survival were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study population (n = 8156) was categorized into 6 trajectories: persistent-ultralow (n = 2351), persistent-low (n = 2474), gradually decrease (n = 401), persistent-medium (n = 1727), slightly increase (n = 909), and around-upper-limit (n = 394). The median follow-up time was 7.8 years, and the median time frame in which CEA was measured to determine trajectory was 2.6 years. The persistent-ultralow group had the highest 10-year overall survival (85.1%) and disease-free survival (82.7%). The around-upper-limit group had the lowest 10-year overall survival (55.5%) and disease-free survival (53.4%). The adjusted HR trend was comparable to the crude HR of the persistent-ultralow group. Consequently, the higher initial serum CEA groups had higher HRs of overall survival and disease-free survival. The adjusted HR of overall survival was 2.96 (95% CI, 2.39-3.66) and of disease-free survival was 2.66 (95% CI, 2.18-3.69) for the around-upper-limit groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The postoperative serum CEA trajectory is an independent factor associated with long-term outcomes. Although CEA levels were all within normal range, higher levels of postoperative serum CEA trajectory correlated with worse long-term oncological outcomes. See Video Abstract.</AbstractText><AbstractText Label="TRAYECTORIAS DE MARCADORES TUMORALES Y ANLISIS DE SUPERVIVENCIA EN PACIENTES CON RANGOS NORMALES DE ANTGENO CARCINOEMBRIONARIO POSTERIOR A RESECCIN DE CNCER COLORRECTAL" NlmCategory="UNASSIGNED">ANTECEDENTES:La evidencia sobre el CEA post operatorio para la predicci&#xf3;n de los resultados a largo plazo del c&#xe1;ncer colorrectal sigue siendo controversial, especialmente en pacientes con CEA post quir&#xfa;rgico normal.OBJETIVO:Investigar la diferencia de riesgo entre diferentes trayectorias postoperatorias del CEA en pacientes con CEA post quir&#xfa;rgico normal tras la resecci&#xf3;n curativa del c&#xe1;ncer colorrectal.DISE&#xd1;O:Este estudio de cohorte se realiz&#xf3; en un centro oncol&#xf3;gico integral e incluy&#xf3; datos recuperados de una base de datos recopilada prospectivamente entre enero de 2006 y diciembre de 2018.AJUSTES:Estudio de cohorte retrospectivo.PACIENTES:Se incluyeron pacientes con el diagnostico de CCR que fueron sometidos a cirug&#xed;a por adenocarcinoma colorrectal primario en estadio I-III. Se excluyeron pacientes con CEA postoperatorio &gt;5&#x2009;ng/mL.INTERVENCIONES:Se realiz&#xf3; una resecci&#xf3;n radical curativa estandarizada.PRINCIPALES MEDIDAS DE RESULTADO:Se analizaron la supervivencia general a diez a&#xf1;os y la supervivencia libre de enfermedad.RESULTADOS:La poblaci&#xf3;n de estudio (n = 8156) fue clasificada en seis trayectorias, que incluyeron ultrabajo persistente (n = 2351), bajo persistente (n = 2474), disminuci&#xf3;n gradual (n = 401), medio persistente (n = 1727), aumento leve (n = 909) y alrededor del l&#xed;mite superior (n = 394). La mediana del tiempo de seguimiento fue de 7,8 a&#xf1;os y la mediana del per&#xed;odo de tiempo en el que el CEA fue medido para determinar la trayectoria fue de 2,6 a&#xf1;os. El grupo ultrabajo persistente tuvo la mayor supervivencia general a 10 a&#xf1;os (85,1 %) y supervivencia libre de enfermedad (82,7 %). El grupo alrededor del l&#xed;mite superior tuvo la supervivencia general a 10 a&#xf1;os m&#xe1;s baja (55,5 %) y la supervivencia libre de enfermedad (53,4 %). La tendencia del &#xed;ndice de riesgo ajustado fue comparable al &#xed;ndice de riesgo bruto del grupo ultrabajo persistente. En consecuencia, los grupos con CEA s&#xe9;rico iniciales m&#xe1;s altos ten&#xed;an &#xed;ndices de riesgos m&#xe1;s altos de supervivencia general y supervivencia libre de enfermedad. Los &#xed;ndices de riesgos ajustados de supervivencia general/supervivencia libre de enfermedad fueron 2,96/2,66 (intervalo de confianza del 95 %: 2,39-3,66/2,18-3,69) para los grupos cercanos al l&#xed;mite superior.LIMITACIONES:El estudio estuvo limitado por su dise&#xf1;o retrospectivo.CONCLUSIONES:La trayectoria del CEA s&#xe9;rico postoperatorio es un factor independiente asociado con resultados a largo plazo. Aunque los niveles de CEA se encontraban todos dentro del rango normal, los niveles m&#xe1;s altos de trayectoria del CEA en suero posoperatorio se correlacionaron con peores resultados oncol&#xf3;gicos a largo plazo. (Traducci&#xf3;n-Dr Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Yih-Jong</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Hsin-Yin</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine, Taipei MacKay Memorial Hospital, Taipei City, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Yu-Jen</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Le-Yin</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program of Data Science, National Taiwan University and Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Wen-Sy</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Chun-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jong</LastName><ForeName>Bor-Kang</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Jeng-Fu</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Chang Gung University, Taoyuan City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37594896</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002894</ArticleId><ArticleId IdType="pii">00003453-202401000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzmaurice C, Abate D, Abbasi N, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749&#x2013;1768.</Citation></Reference><Reference><Citation>Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018;4:309&#x2013;315.</Citation></Reference><Reference><Citation>Ramphal W, Boeding JRE, van Iwaarden M, et al. Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer. Int J Biol Markers. 2019;34:60&#x2013;68.</Citation></Reference><Reference><Citation>Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943&#x2013;947.</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 2.2023. NCCN; 2023. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf .</Citation></Reference><Reference><Citation>Argiles G, Tabernero J, Labianca R, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1291&#x2013;1305.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Moranta F, Sal&#xf3; J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24:386&#x2013;393.</Citation></Reference><Reference><Citation>Bhatti I, Patel M, Dennison AR, Thomas MW, Garcea G. Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. Int J Surg. 2015;16:123&#x2013;128.</Citation></Reference><Reference><Citation>Primrose JN, Perera R, Gray A, et al.; FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263&#x2013;270.</Citation></Reference><Reference><Citation>K&#xf6;rner H, S&#xf6;reide K, Stokkeland PJ, S&#xf6;reide JA. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol. 2007;14:417&#x2013;423.</Citation></Reference><Reference><Citation>Sorensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence&#x2014;a systematic review. Int J Surg. 2016;25:134&#x2013;144.</Citation></Reference><Reference><Citation>Hung H, You J, Chiang J, et al. Why recurrence was initially suspected during colorectal cancer postoperative surveillance?: a retrospective analysis. Medicine (Baltim). 2020;99:e22803.</Citation></Reference><Reference><Citation>Verberne CJ, Zhan Z, van den Heuvel E, et al. Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging: results of the randomized &#x201c;CEAwatch&#x201d; trial. Eur J Surg Oncol. 2015;41:1188&#x2013;1196.</Citation></Reference><Reference><Citation>Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13:645&#x2013;650.</Citation></Reference><Reference><Citation>Nakamura Y, Shida D, Tanabe T, et al. Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer. Cancer Med. 2020;9:653&#x2013;662.</Citation></Reference><Reference><Citation>Shinkins B, Primrose JN, Pugh SA, et al. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. Br J Surg. 2018;105:658&#x2013;662.</Citation></Reference><Reference><Citation>Li C, Zhang D, Pang X, et al. Trajectories of perioperative serum tumor markers and colorectal cancer outcomes: a retrospective, multicenter longitudinal cohort study. EBioMedicine. 2021;74:103706.</Citation></Reference><Reference><Citation>Yakabe T, Nakafusa Y, Sumi K, et al. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol. 2010;17:2349&#x2013;2356.</Citation></Reference><Reference><Citation>Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65:205&#x2013;210.</Citation></Reference><Reference><Citation>Nagin DS, Odgers CL. Group-based trajectory modeling (nearly) two decades later. J Quant Criminol. 2010;26:445&#x2013;453.</Citation></Reference><Reference><Citation>Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35:542&#x2013;571.</Citation></Reference><Reference><Citation>Nagin DS, Jones BL, Passos VL, Tremblay RE. Group-based multi-trajectory modeling. Stat Methods Med Res. 2018;27:2015&#x2013;2023.</Citation></Reference><Reference><Citation>McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32:3388&#x2013;3414.</Citation></Reference><Reference><Citation>Tein JY, Mazza GL, Gunn HJ, et al. Multigroup propensity score approach to evaluating an effectiveness trial of the new beginnings program. Eval Health Prof. 2018;41:290&#x2013;320.</Citation></Reference><Reference><Citation>Moran AE, Liu K. Invited commentary: quantifying the added value of repeated measurements. Am J Epidemiol. 2017;186:908&#x2013;909.</Citation></Reference><Reference><Citation>Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109&#x2013;138.</Citation></Reference><Reference><Citation>Dayimu A, Wang C, Li J, et al. Trajectories of lipids profile and incident cardiovascular disease risk: a longitudinal cohort study. J Am Heart Assoc. 2019;8:e013479.</Citation></Reference><Reference><Citation>Raghavan S, Liu WG, Berkowitz SA, et al. Association of glycemic control trajectory with short-term mortality in diabetes patients with high cardiovascular risk: a joint latent class modeling study. J Gen Intern Med. 2020;35:2266&#x2013;2273.</Citation></Reference><Reference><Citation>Ke C, Stukel TA, Shah BR, et al. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: a population-based observational study. PLoS Med. 2020;17:e1003316.</Citation></Reference><Reference><Citation>Li Z, Li C, Pu H, et al. Trajectories of perioperative serum carcinoembryonic antigen and colorectal cancer outcome: a retrospective, multicenter longitudinal cohort study. Clin Transl Med. 2021;11:e293.</Citation></Reference><Reference><Citation>Suzuki Y, Ogura A, Uehara K, et al. The carcinoembryonic antigen ratio is a potential predictor of survival in recurrent colorectal cancer. Int J Clin Oncol. 2021;26:1264&#x2013;1271.</Citation></Reference><Reference><Citation>Lee WS, Baek JH, Kim KK, Park YH. The prognostic significant of percentage drop in serum CEA post curative resection for colon cancer. Surg Oncol. 2012;21:45&#x2013;51.</Citation></Reference><Reference><Citation>Beom SH, Shin SJ, Kim CG, et al. Clinical significance of preoperative serum carcinoembryonic antigen within the normal range in colorectal cancer patients undergoing curative resection. Ann Surg Oncol. 2020;27:2774&#x2013;2783.</Citation></Reference><Reference><Citation>Huh JW, Kim CH, Lim SW, Kim HR, Kim YJ. Factors predicting long-term survival in colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. J Cancer Res Clin Oncol. 2013;139:1449&#x2013;1455.</Citation></Reference><Reference><Citation>Fenqi D, Yupeng L, Qiuju Z, et al. Early postoperative serum carcinoembryonic antigen is a stronger independent prognostic factor for stage II colorectal cancer patients than T4 stage and preoperative CEA. Front Oncol. 2021;11:758509.</Citation></Reference><Reference><Citation>Lan YT, Lin JK, Lin TC, et al. Prognostic significance of perioperative change of CEA level in colorectal patients when pre-operative level is normal. Hepatogastroenterology. 2012;59:717&#x2013;720.</Citation></Reference><Reference><Citation>Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Dis. 2007;9:527&#x2013;531.</Citation></Reference><Reference><Citation>Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. Ann Surg Oncol. 2012;19:3422&#x2013;3431.</Citation></Reference><Reference><Citation>Lin PC, Lin JK, Lin CC, et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis. 2012;27:1333&#x2013;1338.</Citation></Reference><Reference><Citation>Wang JY, Lin SR, Wu DC, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res. 2007;13:2406&#x2013;2413.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>